RegulatoryApr 15, 2026, 06:07 AM
Health Canada Approves ARS Pharma's neffy for Anaphylaxis
AI Summary
ARS Pharmaceuticals announced Health Canada has approved neffy 2 mg (epinephrine nasal spray) for the emergency treatment of severe allergic reactions in adults and children weighing 30 kg or more. This marks the first needle-free epinephrine option in Canada, with availability expected in Summer 2026 through its partnership with ALK-Abelló. ARS Pharma has already received $155 million in upfront and milestone payments from ALK and is eligible for up to an additional $310 million.
Key Highlights
- Health Canada approved neffy 2 mg for adults and children >30 kg.
- neffy is expected to be available in Canada in Summer 2026.
- ARS Pharma received $155M from ALK-Abelló, eligible for up to $310M more.
- neffy 2 mg was previously approved in China in December 2025.
- ARS Pharma plans to file for neffy 1 mg dose approval in Canada and China.